Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...
The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...
Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...
DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback